MA38239A1 - Nouveaux dérivés de pyridine - Google Patents

Nouveaux dérivés de pyridine

Info

Publication number
MA38239A1
MA38239A1 MA38239A MA38239A MA38239A1 MA 38239 A1 MA38239 A1 MA 38239A1 MA 38239 A MA38239 A MA 38239A MA 38239 A MA38239 A MA 38239A MA 38239 A1 MA38239 A1 MA 38239A1
Authority
MA
Morocco
Prior art keywords
pyridine derivatives
new pyridine
new
compound
formula
Prior art date
Application number
MA38239A
Other languages
English (en)
Inventor
Uwe Grether
Atsushi Kimbara
Matthias Nettekoven
Stephan Roever
Mark Rogers-Evans
Tanja Schulz-Gasch
Beat Frei
Luca Gobbi
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA38239A1 publication Critical patent/MA38239A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La présente invention concerne un composé de formule (i) où r1 à r3 sont tels que définis dans la description et les revendications. Le composé de formule (i) peut être utilisé comme médicament.
MA38239A 2012-12-07 2013-12-02 Nouveaux dérivés de pyridine MA38239A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12196022 2012-12-07
PCT/EP2013/075225 WO2014086705A1 (fr) 2012-12-07 2013-12-02 Nouveaux dérivés de pyridine

Publications (1)

Publication Number Publication Date
MA38239A1 true MA38239A1 (fr) 2017-03-31

Family

ID=47290804

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38239A MA38239A1 (fr) 2012-12-07 2013-12-02 Nouveaux dérivés de pyridine

Country Status (34)

Country Link
US (1) US9522886B2 (fr)
EP (2) EP3357918A1 (fr)
JP (1) JP6426618B2 (fr)
KR (1) KR20150092282A (fr)
CN (2) CN104837831B (fr)
AR (1) AR093843A1 (fr)
AU (2) AU2013354278B2 (fr)
BR (1) BR112015012919A2 (fr)
CA (1) CA2890100A1 (fr)
CL (1) CL2015001536A1 (fr)
CO (1) CO7350620A2 (fr)
CR (1) CR20150250A (fr)
DK (1) DK2928881T3 (fr)
EA (1) EA026669B1 (fr)
ES (1) ES2668690T3 (fr)
HK (1) HK1208031A1 (fr)
HR (1) HRP20180672T1 (fr)
HU (1) HUE036911T2 (fr)
IL (1) IL239075B (fr)
LT (1) LT2928881T (fr)
MA (1) MA38239A1 (fr)
MX (1) MX2015007155A (fr)
NO (1) NO2928881T3 (fr)
PE (1) PE20151025A1 (fr)
PH (1) PH12015501083A1 (fr)
PL (1) PL2928881T3 (fr)
PT (1) PT2928881T (fr)
RS (1) RS57143B1 (fr)
SG (2) SG11201504416XA (fr)
SI (1) SI2928881T1 (fr)
TW (1) TWI600645B (fr)
UA (1) UA114656C2 (fr)
WO (1) WO2014086705A1 (fr)
ZA (1) ZA201503969B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014135507A1 (fr) 2013-03-07 2014-09-12 F. Hoffmann-La Roche Ag Nouveaux dérivés de pyrazole
UA116239C2 (uk) 2013-03-26 2018-02-26 Ф. Хоффманн-Ля Рош Аг Нові похідні піридину
CA2903588C (fr) 2013-05-02 2021-10-26 F. Hoffmann-La Roche Ag Derives de la purine en tant qu'agonistes du recepteur cb2
RS56313B1 (sr) 2013-05-02 2017-12-29 Hoffmann La Roche Derivati pirolo[2,3-d]pirimidina kao agonisti cb2 receptora
LT3483163T (lt) 2013-09-06 2021-09-10 F. Hoffmann-La Roche Ag Triazol[4,5-d]pirimidino dariniai kaip cb2 receptorių antagonistai
WO2015150438A1 (fr) * 2014-04-04 2015-10-08 F. Hoffmann-La Roche Ag Pyridine-2-carboxamides bisubstitués en 5,6 servant d'agonistes du récepteur cannabinoïde
US10214508B2 (en) 2014-06-13 2019-02-26 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
PL3386951T3 (pl) * 2015-12-09 2020-06-29 F. Hoffmann-La Roche Ag Pochodne fenylowe jako agoniści receptora kannabinoidowego typu 2
WO2017107089A1 (fr) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. Modulateurs allostériques 3-(1h-pyrazol-4-yl)pyridine du récepteur muscarinique m4 de l'acétylcholine
JP7300398B2 (ja) 2017-06-20 2023-06-29 エフ． ホフマン－ラ ロシュ アーゲー ピリジン誘導体
EP3781551A1 (fr) * 2018-04-18 2021-02-24 Basf Se Monoester de d-glucaro-6,3-lactone et son procédé de préparation
EP3813888A1 (fr) 2018-06-27 2021-05-05 F. Hoffmann-La Roche AG Ligand du récepteur cannabinoïde 2 radiomarqué
EP3814337A1 (fr) 2018-06-27 2021-05-05 F. Hoffmann-La Roche AG Dérivés de pyridine et de pyrazine en tant qu'agonistes de cannabinoïde 2 préférentiels
JP7478672B2 (ja) * 2018-06-27 2024-05-07 エフ． ホフマン－ラ ロシュ アーゲー カンナビノイド受容体２の阻害剤としての新規なアゼチジン置換ピリジン及びピラジン化合物
CN114502538A (zh) * 2019-09-30 2022-05-13 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的经取代的3,4-二氢喹唑啉
EP4211171A2 (fr) 2020-09-10 2023-07-19 Precirix N.V. Fragment d'anticorps contre fap
CA3216874A1 (fr) * 2021-04-19 2022-10-27 Chemocentryx, Inc. Azetidinyl-acetamides utilises comme inhibiteurs de cxcr7
WO2023203135A1 (fr) 2022-04-22 2023-10-26 Precirix N.V. Anticorps radiomarqué amélioré
WO2023213801A1 (fr) 2022-05-02 2023-11-09 Precirix N.V. Pré-ciblage

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2076499B1 (fr) 2006-10-04 2010-05-12 F.Hoffmann-La Roche Ag Dérivés de pyrazine-2-carboxamide en tant que modulateurs du récepteur cb2
WO2012031817A1 (fr) 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Détermination des niveaux de protéine abca1 dans des cellules
UY33874A (es) * 2011-01-26 2012-08-31 Sanofi Aventis Derivados de ácido 3-heteroaroilamino-propiónico sustituidos y su uso como sustancias farmacéuticas
US9321727B2 (en) * 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor

Also Published As

Publication number Publication date
CL2015001536A1 (es) 2015-10-23
CN104837831B (zh) 2017-10-31
MX2015007155A (es) 2015-10-14
PE20151025A1 (es) 2015-07-15
PT2928881T (pt) 2018-05-07
CR20150250A (es) 2015-06-11
TW201427951A (zh) 2014-07-16
ES2668690T3 (es) 2018-05-21
UA114656C2 (uk) 2017-07-10
TWI600645B (zh) 2017-10-01
SG11201504416XA (en) 2015-07-30
AU2013354278A1 (en) 2015-05-14
PH12015501083B1 (en) 2015-08-03
SG10201800170YA (en) 2018-02-27
RS57143B1 (sr) 2018-07-31
ZA201503969B (en) 2016-04-28
HRP20180672T1 (hr) 2018-06-01
AU2017279648A1 (en) 2018-01-18
AU2013354278B2 (en) 2017-10-12
KR20150092282A (ko) 2015-08-12
NO2928881T3 (fr) 2018-08-11
CA2890100A1 (fr) 2014-06-12
EA026669B1 (ru) 2017-05-31
HK1208031A1 (en) 2016-02-19
CO7350620A2 (es) 2015-08-10
PH12015501083A1 (en) 2015-08-03
US20150307452A1 (en) 2015-10-29
PL2928881T3 (pl) 2018-07-31
US9522886B2 (en) 2016-12-20
HUE036911T2 (hu) 2018-08-28
CN104837831A (zh) 2015-08-12
IL239075B (en) 2018-11-29
LT2928881T (lt) 2018-06-11
EA201591064A1 (ru) 2015-09-30
WO2014086705A1 (fr) 2014-06-12
BR112015012919A2 (pt) 2017-07-11
JP2016501240A (ja) 2016-01-18
CN107674061A (zh) 2018-02-09
JP6426618B2 (ja) 2018-11-21
EP2928881A1 (fr) 2015-10-14
EP3357918A1 (fr) 2018-08-08
IL239075A0 (en) 2015-07-30
DK2928881T3 (en) 2018-05-28
EP2928881B1 (fr) 2018-03-14
AR093843A1 (es) 2015-06-24
SI2928881T1 (en) 2018-07-31

Similar Documents

Publication Publication Date Title
MA38239A1 (fr) Nouveaux dérivés de pyridine
MA40308A1 (fr) Pyridine-2- amides utiles comme agonistes de cb2
MA38404A1 (fr) Nouveaux dérivés de pyridine
MA38238A1 (fr) Pyridine-2-amides utiles comme agonistes de cb2
MA38826B1 (fr) Nouveaux dérivés de triazolo[4,5-d]pyrimidine
MA38403A1 (fr) Nouveaux dérivés de pyrazole modulateurs specifiques de cb2
MA35663B1 (fr) Dérivés de [1, 2, 3]triazolo [4, 5 -d] pyrimidine comme agonistes des récepteurs aux cannabinoïdes 2
EA201591527A1 (ru) Новые производные пиридина
MA39172A1 (fr) Dérivés bicycliques hétérocycliques comme inhibiteurs de bromodomaines
MA38460A1 (fr) Dérivés de la purine en tant qu'agonistes du récepteur cb2
RS54873B1 (sr) Policiklična-karbamoilpiridonska jedinjenja i njihova farmaceutska upotreba
UA111640C2 (uk) ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
MA35434B1 (fr) Amino-quinazolines en tant qu'inhibiteurs de kinase
UA108101C2 (xx) Похідні n3-заміщених n1-сульфоніл-5-фторпіримідинонів
TN2015000084A1 (fr) Pyridinones bicycliques nouvelles
MA38583A1 (fr) Dérivés de dolastatine 10 et d'auristatines
MA38555A1 (fr) Dérivés de pyrrolo[2,3-d]pyrimidine en tant qu'agonistes du récepteur cb2
EA201790939A1 (ru) ТРИАЗОЛО[4,5-d]ПИРИМИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ КАННАБИНОИДНЫХ РЕЦЕПТОРОВ ТИПА 2
MA35816B1 (fr) Dérivés d'aniline, leur préparation et leur application thérapeutique
MA43400B1 (fr) Dérivés de phényle en tant qu'agonistes du récepteur cannabinoïde 2
EA201400058A1 (ru) Соединения и композиции на основе амидопиридиловых эфиров и их применение против паразитов
MA33985B1 (fr) Dérivés fluorés de 3-hydroxypyridin-4-ones
IN2015DN00728A (fr)
MA37920A1 (fr) Amino-quinoléines servant d'inhibiteurs de kinase